1 Original Article

2	
3	Long-term Air Pollution Exposure are Associated with Higher Incidence of ST-
4	elevation Myocardial Infarction and In-hospital Cardiogenic Shock
5	
6	Jinah Cha, BS <sup>1,3*</sup> , Se Yeon Choi, PhD <sup>2*</sup> , Seung-Woon Rha, MD, PhD <sup>1,3</sup> , Byoung Geol Choi,
7	PhD <sup>2</sup> , Jae Kyeong Byun, PhD <sup>2</sup> , Sujin Hyun, BS <sup>4</sup> , Min Woo Lee, PhD <sup>5</sup> , Jaeho Kang, MD <sup>3</sup> ,
8	Wonsang Chu, MD <sup>3</sup> , Soohyung Park, MD <sup>3</sup> , Eun Jin Park, MD, PhD <sup>3</sup> , Dong Oh Kang, MD,
9	PhD <sup>3</sup> , Cheol Ung Choi, MD, PhD <sup>3</sup> , Suhng Wook Kim, PhD <sup>6</sup> , Myung ho Jeong, MD, PhD <sup>7</sup>
10	and the other Korea Acute Myocardial Infarction Registry (KAMIR) investigators
11	
12	<sup>1</sup> BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of
13	Medicine, Seoul, Republic of Korea;
14	<sup>2</sup> Cardiovascular Research Institution, Korea University College of Medicine, Seoul, Republic
15	of Korea;
16	<sup>3</sup> Department of Cardiology, Cardiovascular Center, Guro Hospital, Korea University College
17	of Medicine, Seoul, Republic of Korea;
18	<sup>4</sup> Transdisciplinary Major in Learning Health Systems, Department of Healthcare Sciences,
19	Graduate School, Korea University;
20	<sup>5</sup> Research Institute of Health Science, Korea University, Seoul, Korea;
21	<sup>6</sup> School of Health and Environmental Science, College of Health Sciences, Korea University,
22	Seoul, Korea;
23	<sup>7</sup> Department of Cardiology, Cardiovascular Center, Chonnam National University Hospital,
24	Gwangju, Republic of Korea.

- 25
- <sup>26</sup> \* The first two authors (J Cha and SY Choi) contributed equally to this article.
- 27 Short title: Impact of Long-term Air Pollution Exposure on AMI
- 28 Correspondence to: Seung-Woon Rha, MD, Ph.D.;
- 29 Cardiovascular Center,
- 30 Korea University Guro Hospital,
- 31 148, Gurodong-ro, Guro-gu, Seoul 08308, Korea;
- 32 Tel.: +82-2-2626-3020;
- 33 Fax: +82-2-864-3062;
- 34 E-mail: <u>swrha617@yahoo.co.kr</u>
- 35 Total word count: 5,687

#### 36 Abstract

37 Background: Previous studies have reported the association between myocardial infarction 38 (MI) and air pollution (AP). However, limited information is available regarding the long-39 term effects of AP on the relative incidence rates of ST-elevation MI (STEMI) and Non-ST-40 elevation MI (NSTEMI). 41 Methods: Study subjects were enrolled from the Korea Acute MI registry (KAMIR) and 42 KAMIR-National Institutes of Health (NIH). A total of 45,619 eligible patients with AMI 43 were enrolled between January 2006 and December 2015. We investigated the association 44 between long-term exposure to AP and compared the incidence of STEMI with those of 45 NSTEMI. Mixed-effect regression models were used to examine the association between the 46 annual average ambient AP before MI onset and the incidence of STEMI compared with that 47 of NSTEMI, and to evaluate the association of AP with the incidence of in-hospital 48 cardiogenic shock. 49 **Results:** After mixed-effect regression model analysis, each 1  $\mu$ g/m<sup>3</sup> increase in particulate 50 matter (PM) 10  $\mu$ m or less in diameter (PM<sub>10</sub>) was associated with increased incidence of 51 STEMI compared with NSTEMI (odds ratio [OR]:1.009, 95% Confidence Interval [CI]: 1.002–1.016; p = 0.012). For in-hospital cardiogenic shock complication, each 1 µg/m<sup>3</sup> 52 53 increase in PM<sub>10</sub> and 1 part per billion increase in SO<sub>2</sub> were associated with increased risk, 54 PM<sub>10</sub> (OR:1.033, 95% CI, 1.018–1.050; p < 0.001), SO<sub>2</sub> (OR:1.104, 95% CI, 1.006–1.212; p 55 = 0.037), respectively. 56 Conclusion: A high concentration of air pollutants, particularly PM<sub>10</sub>, was an environmental 57 risk factor for an increase incidence of development of STEMI. PM<sub>10</sub> and SO<sub>2</sub> were found to 58 be risk factors for in-hospital cardiogenic shock complications. Policy-level strategies and 59 clinical efforts to reduce AP exposure are necessary to prevent the incidence of STEMI and 60 severe cardiovascular complications.

-1-

61	Key Words: Air pollution, Particulate matter, Myocardial infarction, Cardiogenic Shock
62	
63	Clinical Perspective
64	What is new?
65	- This study determined the long-term association between air pollutants and the
66	relative incidence of STEMI and NSTEMI using a large patient registry dataset.
67	- Air pollution, particularly involving $PM_{10}$ , was associated with an increased risk of
68	STEMI compared with NSTEMI.
69	- In patients with Acute Myocardial Infarction (AMI), PM <sub>10</sub> and SO <sub>2</sub> were found to be
70	risk factors for the development of in-hospital cardiogenic shock complications.
71	
72	What are the clinical implications?
73	- The findings of this study should be considered a milestone in developing a policy to
74	reduce AP exposure and prevent STEMI incidence in high-risk MI patients.
75	- Clinical efforts are necessary to reduce the incidence rates of adverse cardiovascular
76	complications such as cardiogenic shock.
77	- Mixed-effect regression model analysis for AP exposure is useful in providing
78	information that can enable early identification of STEMI patients and those with
79	severe complication cardiogenic shock risks.
80	

# 81 Non-standard Abbreviations and Acronyms

ACS	acute coronary syndrome
AMI	acute myocardial infarction
AP	air pollution
BMI	body mass index
CAD	coronary artery disease
CI	confidence intervals
CO	carbon monoxide
CVA	cerebrovascular disease
DL	dyslipidemia
DM	diabetes mellitus
HF	heart failure
HTN	hypertension
IHD	Ischemic heart diseases
LVEF	left ventricular ejection fraction
MI	myocardial infarction
MVD	multivessel coronary artery disease
$NO_2$	nitric dioxide
NSTEMI	Non-ST-elevation myocardial infarction
$O_3$	ozone
OR	odds ratios
PCI	percutaneous coronary intervention
$PM_{10}$	particulate matter 10 µm or less in diameter
PM <sub>2.5</sub>	particulate matter 2.5 $\mu$ m or less in diameter
ppm	part per million
$SO_2$	sulfur dioxide
STEMI	ST-elevation myocardial infarction

#### 90 Introduction

91 Ischemic heart diseases (IHD) including acute myocardial infarction (AMI) are a 92 public health burden and are a leading cause of mortality and morbidity worldwide. AMI is a major cause of mortality in the Asia-Pacific region.<sup>1-4</sup> In particular, in patients with coronary 93 94 artery disease (CAD), air pollution (AP) is related to complications such as increased hospitalization, re-admission, and early mortality.<sup>5-7</sup> Exposure to highly polluted air is one of 95 the environmental factors that triggers AMI.<sup>8</sup> There is a relationship between short and long-96 97 term effects of exposure to AP; however, long-term exposure effects outnumber the sum of all short-term effects.<sup>9</sup> Most of the studies have focused on the association between the 98 effects of short-term exposure to AP and AMI.<sup>8, 10, 11</sup> Our previous studies demonstrated that 99 100 AP exposure was associated with overall adverse clinical outcomes, including mortality, in AMI patients based on short and long-term exposure and follow-up periods.<sup>12, 13</sup> However, 101 102 only few studies have reported on long-term AP exposure along with comparison between the 103 relative incidence of ST-elevation myocardial infarction(MI, STEMI) and that of Non-ST-104 elevation myocardial infarction (Non-STEMI) and associated adverse effects related to 105 mortality. 106 This study is an extension of our previous study and aimed to clarify the association

107 between the long-term average concentration of AP and the relative risk of developing a 108 STEMI compared to a NSTEMI, as well as the relationship between the annual average 109 concentration of AP and cardiogenic shock, which was observed to be high in STEMI 110 patients.

111

112 Methods

#### 113 Study Protocols and Population

-4-

114	The study subjects were enrolled in the Korea AMI registry (KAMIR) and KAMIR-
115	National Institutes of Health (NIH). The KAMIR study protocol has been introduced
116	previously. <sup>14</sup> KAMIR and KAMIR-NIH are nationwide prospective multicenter registration
117	study series that aim to establish treatment guidelines and derive risk factors through the
118	analysis of various clinical characteristics and follow-up of Korean AMI patients since
119	October 2005 onwards. A flowchart of the study is shown in Figure 1. A total of 50,130
120	patients with AMI were enrolled in the KAMIR and KAMIR-NIH between January 2006 and
121	December 2015. The exclusion criteria were as follows: (1) date of symptom onset before
122	2006, (2) missing date of symptom onset, (3) age $< 18$ years, and (4) no final diagnosis of MI
123	at discharge.
124	Ethics approval
125	This study was approved by the Institutional Review Board (IRB) of Korea
126	University Guro Hospital (KUGH, #2016GR0740) and was conducted in accordance with the
127	principles of the Declaration of Helsinki.
128	AP measurement
129	Hourly AP concentrations were provided by the Korean Ministry of Environment
130	(http://www.airkorea.or.kr). In 2001, 329 monitoring stations nationwide began measuring
131	the concentration of air pollutants. Measurement of air pollutants involved the $\beta$ -ray
132	absorption method for particulate matter (PM) 10 $\mu$ m or less in diameter (PM <sub>10</sub> ), the non-
133	dispersive infrared method for carbon monoxide (CO), the pulse ultraviolet fluorescence
134	method for sulfur dioxide (SO <sub>2</sub> ), the chemiluminescence method for nitric dioxide (NO <sub>2</sub> ), and
135	the ultraviolet photometric method for ozone ( $O_3$ ). The concentration measurement of PM 2.5
136	$\mu$ m or less in diameter (PM <sub>2.5</sub> ) began in January 2015; therefore, annual average

-5-

137 concentration values were not available during the patient enrollment period (2006–2015)138 and was excluded.

139	We transformed collected data into the daily average value, and then, the annual
140	average value of air pollutants before the symptom day was calculated the way previous
141	research was performed. <sup>13</sup> Each monitoring station was matched by the closest distance in a
142	straight line to 68 hospitals registered in KAMIR to measure individual exposure
143	concentration of air pollutants. Monitoring stations were selected based on hospital admission
144	addresses for the following reasons: (1) Patient addresses were not included in the
145	multicenter registry data. (2) As AMI is an emergency, it is assumed that the patient was
146	admitted to an emergency room close to the workplace and residence at the time of symptom
147	onset. If a pollutant measurement was missed due to a connection error with a monitoring
148	station, the measurement of the next-nearest monitoring station was assigned. Symptom date
149	was defined as the first occurrence of MI-related symptoms such as chest pain or dyspnea.
150	Study Definitions
151	The diagnosis of AMI was defined as an elevation in cardiac biomarkers (creatinine
152	kinase-MB, and troponin I, or T) with typical changes on 12 leads electrocardiogram (ECG)
153	or clinical symptoms. STEMI was diagnosed as a new ST-elevation segment measuring $\geq 1$
154	mm from $\geq 2$ contiguous leads on ECG. Patients with positive cardiac biomarkers but without
155	ECG findings of STEMI were defined as NSTEMI. Cardiogenic shock was defined as a
156	systolic blood pressure <90 mmHg for >30 min, the need for supportive management to
157	maintain systolic blood pressure >90 mmHg, and clinical signs of pulmonary congestion.
158	Individual cardiovascular risk factors, including hypertension (HTN), dyslipidemia
159	(DL), diabetes mellitus (DM), prior cardiovascular disease, heart failure (HF), prior
160	cerebrovascular disease (CVA), and smoking history, were based on self reports by the
161	patient.

-6-

#### 162 Statistical Analysis

- 163 All statistical analyses were performed using R version 4.1.2. (R Core Team, 2021; R: 164 Language and Environment for Statistical Computing; R Foundation for Statistical 165 Computing, Vienna, Austria, URL: https://www.R-project.org/). We compared the clinical and angiographic characteristics using a  $X^2$  test or Fisher's 166 167 exact test for categorical variables and Student's t-test or Mann-Whitney rank test for 168 continuous variables. Categorical data were expressed as percentages, and continuous 169 variables were described as mean  $\pm$  standard deviation. 170 We used generalized logistic mixed effect models with a random effect term for 171 hospitals to examine the associations of each air pollutant with the incidence rate of STEMI 172 and cardiogenic shock complication rates, and to account for hospital and regional effects 173 such as accessibility and treatment plans. Using a multivariable model, we adjusted for 174 potential confounding factors including: age, sex, body mass index (BMI), smoking status, 175 HTN, DM, DL, stroke, HF, previous IHD, and symptom date. STEMI status, percutaneous 176 coronary intervention (PCI), and left ventricular ejection fraction (LVEF), were used to 177 analyze the incidence of cardiogenic shock complications. 178 In the subgroup analysis, several stratified analyses were performed to test the 179 potential effect modifications of the following factors, by including an interaction term: for 180 the STEMI group analysis, the following terms were used: age, sex, HTN, DM, DL, CVA, 181 HF, prior IHD, smoking, family history of CAD. In the cardiogenic shock group, STEMI 182 status, PCI, and LVEF were added. The results were presented as adjusted odds ratios (OR) 183 for logistic regression with corresponding 95% confidence intervals (CI). Statistical 184 significance was defined as a p-value < 0.05. 185
- 186 **Results**

187	A total of 45,619 patients with AMI were enrolled in our study. Of these, 20,526
188	were patients with NSTEMI and 25,093 were patients with STEMI. In our study population,
189	compared with patients with NSTEMI, patients with STEMI were younger, male, had a
190	higher smoking status, and had fewer underlying chronic diseases, such as DM, HTN, and
191	DL. Moreover, patients with STEMI had more Killip class IV and a low LVEF and those
192	were less likely to have a history of cardiovascular diseases, such as HF, CVA, and previous
193	IHD. Among the angiographic parameters, the STEMI group had more PCI as the initial
194	treatment for MI, lower multivessel coronary artery disease (MVD), and the left main artery
195	as the culprit lesion. The cardiogenic shock complication rate during the index hospitalization
196	was significantly higher in the STEMI group (Table 1). Therefore, we analyzed the link
197	between cardiogenic shock events, which are severe cardiovascular complications, and
198	annual AP exposure (Table 4).
199	In Table 2, we observed the median value of annual average concentrations was
200	0.049 part per million (ppm) for SO <sub>2</sub> , 0.6088 ppm for CO, 0.0211 ppm for O <sub>3</sub> , 0.0259 ppm
201	for NO <sub>2</sub> , and 50.53 $\mu$ g/m <sup>3</sup> for PM <sub>10</sub> .
202	In the Spearman rank correlation analysis using the average annual concentrations
203	after the symptom date, most air pollutants showed a positive correlation ( $r = 0.178-0.467$ );
204	however, $O_{3}$ , and other air pollutants, showed a negative correlation (r = -0.2650.609;
205	Figure 2).
206	After mixed-effect regression model analysis, no difference was observed for most
207	air pollutants except $PM_{10}$ , which was associated with increased incidence of STEMI
208	compared with NSTEMI for each 1 $\mu$ g/m <sup>3</sup> increase (odds ratio [OR]:1.009, 95% Confidence
209	Interval [CI]: 1.002–1.016; p=0.012; Table 3). For in-hospital cardiogenic shock
210	complication, each 1 $\mu$ g/m <sup>3</sup> increase of PM <sub>10</sub> and each 1 part per billion (ppb) increase of
211	SO <sub>2</sub> were associated with increased risk: PM <sub>10</sub> (OR:1.033, 95% CI: 1.018–1.050; p<0.001),

-8-

212 SO<sub>2</sub> (OR:1.104, 95% CI: 1.006–1.212; p=0.037), respectively. In contrast, for each 1 ppb

213 increase in O<sub>3</sub> was negatively correlated with cardiogenic shock (OR, 0.891; 95% CI:0.857–

214 0.928; p<0.001; Table 4).

215 When STEMI and each air pollutant were analyzed in subgroups, the results showed 216 there was a significant association with a decrease in STEMI incidence for every 1 ppb 217 increase of NO<sub>2</sub> in CVA patients. In the absence of HTN, there was an increase in STEMI incidence for every 1  $\mu$ g/m<sup>3</sup> increase PM<sub>10</sub> (Figure S1–5). In subgroup analyses used to 218 219 evaluate the risk of cardiogenic shock with AP exposure, it is shown that there was a 220 significant association between increasing cardiogenic shock complication rate and for each 1 221 ppb increase of NO<sub>2</sub> in patients with no history of PCI, for each 1  $\mu$ g/m<sup>3</sup> increase of PM<sub>10</sub> in 222 patients with prior IHD or without PCI treatment, and for each 1 ppb increase in SO<sub>2</sub> with HF 223 patients or prior IHD (Figure S6-10).

### 224 Discussion

225 We performed a large registry-based analysis to evaluate the association between 226 long-term exposure to AP. In this study, using a nationwide prospective clinical registry, we 227 found that increased concentrations of AP increased the risk of STEMI compared with that of 228 NSTEMI and increased the risk of cardiogenic shock complication, which is related to overall 229 mortality. The results of this study showed that long-term exposure to high levels of PM<sub>10</sub> is 230 associated with an increased risk of STEMI. Moreover, this study demonstrates that PM<sub>10</sub> and 231 SO<sub>2</sub> may impact on the development of cardiogenic shock complication in patients with AMI. 232 Air pollutants comprise complex mixtures that are compounded with gases, including SO<sub>2</sub>, NO<sub>2</sub>, CO, O<sub>3</sub>, and PM, including PM<sub>10</sub> and PM<sub>2.5</sub>.<sup>15</sup> Although it may intuitively seem 233 234 that AP poses a health risk mostly in the form of respiratory disease, many epidemiological 235 and clinical studies have suggested that the majority of the adverse effects of AP are

-9-

associated with the cardiovascular system.<sup>16-18</sup> Previous studies demonstrad that AP exposure
is associated with endothelial injury and inflammation, indicating that it can trigger
cardiovascular events.<sup>19-21</sup>

239 Regarding the association between AP and CVD, many studies have demonstrated 240 that short-term exposure to AP increases the incidence of an acute coronary syndrome (ACS).<sup>22-24</sup> In contrast, the present study investigated the effects of long-term exposure to AP, 241 242 which was the major novelty of our research. The number of studies on the long-term effects 243 of AP exposure are increasing. The ESCAPE (European Study of Cohorts for Air Pollution 244 Effects) study, the increase in PM<sub>10</sub> and PM<sub>2.5</sub> during the long-term follow-up period increases the risk of ACS.<sup>25</sup> However, these studies mainly focus on mortality or overall 245 clinical outcome.<sup>17, 25-27</sup> Researchers have rarely compared the risk of developing STEMI 246 247 with that of NSTEMI. To the best of our knowledge, this is the first study to demonstrate a 248 long-term association between AP exposure and the relative incidence of STEMI compared 249 with that of NSTEMI in the Asia-Pacific region. 250 Our present study was shown that the risk of developing STEMI increased compared to 251 NSTEMI according to the 1-year average PM<sub>10</sub> concentration before symptom onset. These 252 results indicate that STEMI contributes more than NSTEMI to an increased risk of MI 253 according to the AP concentration. Studies on short-term exposure have reported that 254 elevated AP exposure highly triggers the development of STEMI compared with that of NSTEMI.<sup>28, 29</sup> However, some studies have also reported greater incidence of NSTEMI than 255 that of STEMI due to AP exposure<sup>30</sup>. The inconsistent results can be attributed to differences 256

- 257 in exposure periods, geographic location, pollutant concentration level, study population, and
- 258 statistical methods used for analysis.<sup>8, 10</sup>
- In addition, this study are meaningful in that we clarified the effect of AP exposure on the risk of severe complications of cardiogenic shock. Our main findings showed that an

-10-

increased AP concentration was associated with an increase incidence of cardiogenic shock complication. Cardiogenic shock occurs in approximately 5–13% of AMI patients.<sup>31</sup> Moreover, AMI itself was an important etiology contributing to 80% incidences of cardiogenic shock.<sup>32</sup> Cardiogenic shock is associated with poor prognosis for high rate of adverse events even with appropriate treatment, with an in-hospital mortality of 20–40% and a 1-year mortality rate of up to 50%.<sup>31</sup>

267 Although the pathophysiology of cardiogenic shock is not fully understood, it is known 268 that the systemic inflammatory response, release of inflammatory cytokines, and increase in 269 the concentration of nitric oxide (NO) are involved in inappropriate vasodilation after 270 peripheral vascular constriction to compensate for the reduction in myocardial contractility.<sup>33,</sup> <sup>34</sup> Exposure to AP is related to oxidative stress and systemic inflammation<sup>14, 16-18</sup> and it 271 272 adversely affects vascular homeostasis through the production of superoxide and the uncoupling of NO synthase.<sup>35</sup> These results add evidence for the development of cardiogenic 273 274 shock and its subsequent poor prognosis.

275 In our previously published study, the 1-year average AP concentration before the onset of symptoms was associated with an increase in 30-day short-term mortality.<sup>13</sup> Studies 276 277 using the same registry reported that in the STEMI group, there was a higher incidence of 278 short-term mortality and cardiogenic shock compared with the incidence found in the NSTEMI group, which is highly correlated with an increase in the risk of cardiac death.<sup>31,36</sup> 279 280 This study strongly suggests that reducing exposure to high concentrations of AP, not only in 281 the high-risk group but also in the low-risk group of AMI, is necessary to reduce the 282 occurrence of potential MI and mortality, even if STEMI appears to be relatively safe 283 because of its younger age and lower co-morbidity rates than NSTEMI. These efforts should 284 be accompanied by policy strategies and clinical practice.

-11-

285 This study has several limitations. First, because of the limited sampling data available for PM<sub>2.5</sub>, the associations with clinical events may have been relatively low. 286 287 Exposure data for PM<sub>2.5</sub>, were available for only one year, 2015, the last year of this research 288 period. Evidence suggests that PM size is related to cardiovascular morbidity and mortality.<sup>27</sup>,  $^{37}$  Further studies with new data are needed to evaluate the impact of PM<sub>2.5</sub> in AMI patients in 289 290 the future with our KAMIR data with later than 2015 registry database. Second, because the 291 patients' addresses were not available, the direct exposure level determined for the patients 292 could be incorrect. It was assumed that patients were admitted to a nearby emergency room at 293 the time of symptom onset. However, some patients who visited other local hospitals or were 294 transferred may have been misclassified, requiring careful interpretation of the results. Third, 295 because of the limitations of the study design, although confounding factors were adjusted for, 296 the results for residential addresses and socioeconomic variables should be carefully 297 considered. We aimed to assess adjusted adequate variables which could be potentially 298 relevant factors using a multivariable model. Finally, although data used in this research were 299 collected by the attending hospitals well-trained, multicenter registry is need to interpret with 300 consideration for several characteristics such as a gap among each hospitals and data such as 301 input errors and misclassification. 302 In conclusion, we observed that high concentration of air pollutants, particularly of 303 PM<sub>10</sub>, which is an environmental risk factor was associated with an increased incidence of

304 STEMI. Moreover,  $PM_{10}$  and  $SO_2$  levels were risk factors for in-hospital cardiogenic shock

305 complication after MI. This study emphasizes on the need of developing a policy-level

306 strategy and clinical efforts to reduce AP exposure and prevent the incidence of STEMI and

307 severe cardiovascular complications.

308

-12-

309	Refere	ence
310 311 312	1.	Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019. <i>Lancet</i> . 2020;396:1204-1222
313 314 315	2.	Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the gbd 2019 study. <i>J Am Coll Cardiol</i> . 2020;76:2982-3021
316 317	3.	Zhao D. Epidemiological features of cardiovascular disease in asia. <i>JACC Asia</i> . 2021;1:1-13
318 319 320	4.	World Health Organization. Regional Office for the Western P. <i>Health at a glance :</i> <i>Asia/pacific 2014 : Measuring progress towards universal health coverage</i> . Paris: OECD Publishing: 2014.
321 322 323 324	5.	von Klot S, Peters A, Aalto P, Bellander T, Berglind N, D'Ippoliti D, et al. Ambient air pollution is associated with increased risk of hospital cardiac readmissions of myocardial infarction survivors in five european cities. <i>Circulation</i> . 2005;112:3073- 3079
325 326 327	6.	Warburton DER, Bredin SSD, Shellington EM, Cole C, de Faye A, Harris J, et al. A systematic review of the short-term health effects of air pollution in persons living with coronary heart disease. <i>Journal of Clinical Medicine</i> . 2019;8:274
328 329 330	7.	Shah AS, Langrish JP, Nair H, McAllister DA, Hunter AL, Donaldson K, et al. Global association of air pollution and heart failure: A systematic review and meta- analysis. <i>Lancet</i> . 2013;382:1039-1048
331 332	8.	Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the triggering of myocardial infarction. <i>Circulation</i> . 2001;103:2810-2815
333 334	9.	Europe WHOROf. <i>Review of evidence on health aspects of air pollution – revihaap project: Technical report.</i> Copenhagen: WHO Regional Office for Europe
335 336 337 338	© wor 10.	Pope CA, 3rd, Muhlestein JB, May HT, Renlund DG, Anderson JL, Horne BD. Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. <i>Circulation</i> . 2006:114:2443-2448
339 340	11.	Chen R, Jiang Y, Hu J, Chen H, Li H, Meng X, et al. Hourly air pollutants and acute coronary syndrome onset in 1.29 million patients. <i>Circulation</i> . 2022;145:1749-1760
341 342 343	12.	Lee MW, Choi BG, Kim SW, Rha SW, Shim MS, Kim DJ, et al. Air pollution and short-term clinical outcomes of patients with acute myocardial infarction. <i>Clin Exp Pharmacol Physiol.</i> 2017;44:631-638
344 345 346	13.	Choi SY, Rha SW, Cha J, Byun JK, Choi BG, Jeong MH. Association of air pollution and 1-year clinical outcomes of patients with acute myocardial infarction. <i>PLoS One</i> . 2022;17:e0272328
347 348 349	14.	Kim JH, Chae SC, Oh DJ, Kim HS, Kim YJ, Ahn Y, et al. Multicenter cohort study of acute myocardial infarction in korea – interim analysis of the korea acute myocardial infarction registry-national institutes of health registry. <i>Circ J</i> . 2016;80:1427-1436
350 351 352	15.	Pope Iii CA, Dockery DW. Health effects of fine particulate air pollution: Lines that connect. <i>Journal of the Air &amp; Waste Management Association (Air &amp; Waste Management Association)</i> . 2006;56:709-742
353 354 355 356	16.	Brook RD, Rajagopalan S, Pope CA, 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, et al. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the american heart association. <i>Circulation</i> . 2010;121:2331-2378

357	17.	Pope CA, 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, et al.
358		Cardiovascular mortality and long-term exposure to particulate air pollution:
359		Epidemiological evidence of general pathophysiological pathways of disease.
360		Circulation. 2004;109:71-77
361	18.	Kampa M, Castanas E. Human health effects of air pollution. <i>Environ Pollut</i> .
362		2008;151:362-367
363	19.	Krishnan RM, Adar SD, Szpiro AA, Jorgensen NW, Van Hee VC, Barr RG, et al.
364		Vascular responses to long- and short-term exposure to fine particulate matter: Mesa
365		air (multi-ethnic study of atherosclerosis and air pollution). J Am Coll Cardiol.
366		2012;60:2158-2166
367	20.	Bind MA, Baccarelli A, Zanobetti A, Tarantini L, Suh H, Vokonas P, et al. Air
368		pollution and markers of coagulation, inflammation, and endothelial function:
369		Associations and epigene-environment interactions in an elderly cohort. <i>Epidemiology</i> .
370		2012;23:332-340
371	21.	Pope CA, 3rd, Bhatnagar A, McCracken JP, Abplanalp W, Conklin DJ, O'Toole T.
372		Exposure to fine particulate air pollution is associated with endothelial injury and
373		systemic inflammation. Circ Res. 2016;119:1204-1214
374	22.	Akbarzadeh MA, Khaheshi I, Sharifi A, Yousefi N, Naderian M, Namazi MH, et al.
375		The association between exposure to air pollutants including $pm(10)$ , $pm(2.5)$ , ozone,
376		carbon monoxide, sulfur dioxide, and nitrogen dioxide concentration and the relative
377		risk of developing stemi: A case-crossover design. Environ Res. 2018:161:299-303
378	23.	Mustafic H, Jabre P, Caussin C, Murad MH, Escolano S, Tafflet M, et al. Main air
379		pollutants and myocardial infarction: A systematic review and meta-analysis. Jama.
380		2012;307:713-721
381	24.	Nuvolone D, Balzi D, Chini M, Scala D, Giovannini F, Barchielli A. Short-term
382		association between ambient air pollution and risk of hospitalization for acute
383		myocardial infarction: Results of the cardiovascular risk and air pollution in tuscany
384		(riscat) study. Am J Epidemiol. 2011;174:63-71
385	25.	Cesaroni G, Forastiere F, Stafoggia M, Andersen ZJ, Badaloni C, Beelen R, et al.
386		Long term exposure to ambient air pollution and incidence of acute coronary events:
387		Prospective cohort study and meta-analysis in 11 european cohorts from the escape
388		project. BMJ. 2014;348:f7412
389	26.	Tonne C, Wilkinson P. Long-term exposure to air pollution is associated with survival
390		following acute coronary syndrome. Eur Heart J. 2013;34:1306-1311
391	27.	Miller KA, Siscovick DS, Sheppard L, Shepherd K, Sullivan JH, Anderson GL, et al.
392		Long-term exposure to air pollution and incidence of cardiovascular events in women.
393		N Engl J Med. 2007;356:447-458
394	28.	Pope CA, Muhlestein JB, Anderson JL, Cannon JB, Hales NM, Meredith KG, et al.
395		Short-term exposure to fine particulate matter air pollution is preferentially associated
396		with the risk of st-segment elevation acute coronary events. J Am Heart Assoc. 2015;4
397	29.	Gardner B, Ling F, Hopke PK, Frampton MW, Utell MJ, Zareba W, et al. Ambient
398		fine particulate air pollution triggers st-elevation myocardial infarction, but not non-st
399		elevation myocardial infarction: A case-crossover study. Part Fibre Toxicol.
400		2014;11:1
401	30.	Ho AFW, Zheng H, Earnest A, Cheong KH, Pek PP, Seok JY, et al. Time-stratified
402		case crossover study of the association of outdoor ambient air pollution with the risk
403		of acute myocardial infarction in the context of seasonal exposure to the southeast
404		asian haze problem. J Am Heart Assoc. 2019;8:e011272

405	31.	Backhaus T, Fach A, Schmucker J, Fiehn E, Garstka D, Stehmeier J, et al.
406		Management and predictors of outcome in unselected patients with cardiogenic shock
407		complicating acute st-segment elevation myocardial infarction: Results from the
408		bremen stemi registry. Clin Res Cardiol. 2018;107:371-379
409	32.	Harjola VP, Lassus J, Sionis A, Køber L, Tarvasmäki T, Spinar J, et al. Clinical
410		picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart
411		Fail. 2015;17:501-509
412	33.	Vahdatpour C, Collins D, Goldberg S. Cardiogenic shock. Journal of the American
413		Heart Association. 2019;8:e011991
414	34.	Diepen Sv, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al.
415		Contemporary management of cardiogenic shock: A scientific statement from the
416		american heart association. Circulation. 2017;136:e232-e268
417	35.	Cherng TW, Paffett ML, Jackson-Weaver O, Campen MJ, Walker BR, Kanagy NL.
418		Mechanisms of diesel-induced endothelial nitric oxide synthase dysfunction in
419		coronary arterioles. Environmental Health Perspectives. 2011;119:98-103
420	36.	Park HW, Yoon CH, Kang SH, Choi DJ, Kim HS, Cho MC, et al. Early- and late-
421		term clinical outcome and their predictors in patients with st-segment elevation
422		myocardial infarction and non-st-segment elevation myocardial infarction. Int J
423		Cardiol. 2013;169:254-261
424	37.	Crouse DL, Peters PA, van Donkelaar A, Goldberg MS, Villeneuve PJ, Brion O, et al.
425		Risk of nonaccidental and cardiovascular mortality in relation to long-term exposure
426		to low concentrations of fine particulate matter: A canadian national-level cohort
427		study. Environ Health Perspect. 2012;120:708-714
428		

### 429 Acknowledgements

430 This study was done with the support of Korean Circulation Society (KCS) to commemorate 431 the 50th Anniversary of KCS. The KAMIR study group of the KSC was as follows: Korea 432 University Guro Hospital, Seoul, Korea (Seung-Woon Rha), Gachon University Gil Medical 433 Center, Incheon, Korea (Tae Hoon Ahn), Wonju Severance Christian Hospital, Wonju, Korea 434 (Junghan Yoon), Seoul National University Hospital, Seoul, Korea (Hyo-Soo Kim), Seoul St. 435 Mary's Hospital, Seoul, Korea (Ki-Bae Seung), Samsung Medical Center, Seoul, Korea 436 (Hyeon-Cheol Gwon), Kyungpook National University Hospital, Daegu, Korea (Shung Chull 437 Chae), Kyung Hee University Hospital at Gangdong, Seoul, Korea (Chong-Jin Kim), Pusan 438 National University Hospital, Busan, Korea (Kwang Soo Cha), Yeungnam University 439 Medical Center, Daegu, Korea (Jung-Hee Lee), Jeonbuk National University Hospital, Jeonju, 440 Korea (Jei Keon Chae), Jeju National University Hospital, Jeju, Korea (Seung-Jae Joo), Seoul 441 National University Bundang Hospital, Seongnam, Korea (Chang-Hwan Yoon), Keimyung 442 University Dongsan Medical Center, Daegu, Korea (Seung-Ho Hur), Chungnam National 443 University Hospital, Daejeon, Korea (In-Whan Seong), Chungbuk National University 444 Hospital, Cheongju, Korea (Kyung-Kuk Hwang), Inje University Haeundae Paik Hospital, 445 Busan, Korea (Doo-Il Kim), Wonkwang University Hospital, Iksan, Korea (Seok Kyu Oh), 446 Gyeongsang National University Hospital, Jinju, Korea (Jin-Yong Hwang), and Chonnam 447 National University Hospital, Gwangju, Korea (Myung Ho Jeong).

### 448 Sources of Funding

449 This research was supported by grants (2020ER630800 and 2022ER090900) from the Korea 450 Centers for Disease Control and Prevention. (https://www.kdca.go.kr/). The funding 451 organization had no role in the design and administration of the study; the collection,

- 452 management, analysis, and interpretation of the data; the preparation, review, or approval of
- 453 the manuscript; nor the decision to submit the manuscript for publication.

## 454 **Disclosures**

- 455 None.
- 456 Supplemental Material
- 457 Figures S1–S10

### 459 Tables

# 460 **Table 1.** Baseline characteristics

Variables	Total	NSTEMI (n=20,526)	STEMI (n=25,093)	P value
Age (year)	$63.82\pm12.77$	$65.10\pm12.40$	$62.77\pm12.97$	< 0.001
Sex (male)	32,921 (72.2)	14,042 (68.4)	18,879 (75.2)	< 0.001
Body Mass Index (kg/m <sup>2</sup> )	$23.98\pm3.25$	$23.94\pm3.27$	$24.01\pm3.23$	0.036
Systolic Blood Pressure (mmHg)	$129.69\pm28.25$	$133.71\pm27.38$	$126.37\pm28.53$	< 0.001
Diastolic Blood Pressure (mmHg)	$78.89 \pm 16.66$	$80.18 \pm 15.87$	$77.82\pm17.22$	< 0.001
Heart Rate (bpm)	$78.19 \pm 19.90$	$79.70\pm19.36$	$76.96\pm20.25$	< 0.001
Left Ventricular Ejection Fraction (%)	$51.96 \pm 11.86$	$53.51 \pm 12.20$	$50.66 \pm 11.41$	< 0.001
Killip Class 4	2,389 (5.2)	552 (2.7)	1,837 (7.3)	< 0.001
Hypertension	22,776 (49.9)	11,203 (54.6)	11,573 (46.1)	< 0.001
Diabetes Mellitus	12,596 (27.6)	6,418 (31.3)	6,178 (24.6)	< 0.001
Dyslipidemia	5,082 (11.1)	2,571 (12.5)	2,511 (10.0)	< 0.001
Cerebrovascular Disease	3,030 (6.6)	1,659 (8.1)	1,371 (5.5)	< 0.001
Heart Failure	842 (1.8)	582 (2.8)	260 (1.0)	< 0.001
Smoking History	26,337 (57.7)	11,077 (54.0)	15,260 (60.8)	< 0.001
Current Smoker	18,853 (41.3)	7,276 (35.4)	11,577 (46.1)	< 0.001
Family History of Heart Disease	3,285 (7.2)	1,501 (7.3)	1,784 (7.1)	0.404
Previous Ischemic Heart Disease	7,027 (15.4)	4,150 (20.2)	2,877 (11.5)	< 0.001
Previous PCI	3,346 (7.3)	1,968 (9.6)	1,378 (5.5)	< 0.001
Previous MI	2,164 (4.7)	1,265 (6.2)	899 (3.6)	< 0.001
Previous CABG	371 (0.8)	268 (1.3)	103 (0.4)	< 0.001
Previous Angina	2,793 (6.1)	1,733 (8.4)	1,060 (4.2)	< 0.001
Initial treatment of MI				
Thrombolysis	990 (2.2)	0 (0.0)	990 (3.9)	< 0.001
CABG	933 (2.0)	556 (2.7)	377 (1.5)	< 0.001
PCI	39,847 (87.3)	16,329 (79.6)	23,518 (93.7)	< 0.001
Multi-Vessel Disease	21,542 (47.2)	9,942 (48.4)	11,600 (46.2)	< 0.001
Left Main Disease	1,661 (3.6)	957 (4.7)	704 (2.8)	< 0.001
Infarct-related artery				
Left Main	886 (1.9)	522 (2.5)	364 (1.5)	< 0.001
Left Anterior Descending Artery	18,963 (41.6)	6,987 (34.0)	11,976 (47.7)	< 0.001
Left Circumflex Artery	6,849 (15.0)	4,596 (22.4)	2,253 (9.0)	< 0.001
Right Coronary Artery	13,489 (29.6)	4,719 (23.0)	8,770 (34.9)	< 0.001
Cardiogenic Shock Complications	2,317 (5.1)	554 (2.7)	1,763 (7.0)	< 0.001

461 Data is expressed as number (percentage), mean  $\pm$  standard deviation.

462 CABG, coronary artery bypass grafting; NSTEMI, non-ST-elevation myocardial infarction;

463 PCI, percutaneous coronary intervention; MI, myocardial infarction; STEMI, ST-elevation

464 myocardial infarction

	SO <sub>2</sub> (ppm)	CO (ppm)	O <sub>3</sub> (ppm)	NO <sub>2</sub> (ppm)	$\mathrm{PM}_{10}(\mu\mathrm{g/m^{s}})$
Min.	0.0014	0.2028	0.0037	0.0070	18.25
Q1	0.0041	0.5312	0.0176	0.0218	44.65
Median	0.0049	0.6088	0.0211	0.0259	50.53
Q3	0.0061	0.7211	0.0244	0.0342	58.67
Max.	0.0136	1.4976	0.0437	0.0812	99.14
IQR	0.0020	0.1899	0.0068	0.0124	14.02
Mean	0.0053	0.6276	0.0210	0.0284	52.57

Table 2. Distribution for annual average air pollution concentration before symptom date. 466

467

CO, carbon monoxide; IQR, interquartile range;  $NO_2$ , nitric dioxide;  $O_3$ , ozone;  $PM_{10}$ , particulate matter 10  $\mu$ m or less in diameter; ppm, part per million; Q1, 1<sup>st</sup> quintile; Q3, 3<sup>rd</sup> 468 quintile. SO<sub>2</sub>, sulfur dioxide. 469

470 **Table 3.** Univariate and multivariate regression analysis of the incidence of STEMI

471 compared with NSTEMI regarding annual average concentration of each air pollutant before472 symptom date.

473

	Univariate		Multivariate	
	OR (95% CI)	P value	OR (95% CI)	P value
SO <sub>2</sub> (ppb)	1.044 (0.998 - 1.093)	0.060	1.041 (0.995 - 1.089)	0.084
CO (ppm)	1.037 (0.978 - 1.100)	0.225	1.036 (0.977 - 1.099)	0.236
O <sub>3</sub> (ppb)	0.990 (0.972 - 1.009)	0.293	0.989 (0.971 - 1.007)	0.239
NO <sub>2</sub> (ppb)	1.000 (0.987 - 1.012)	0.943	0.999 (0.987 - 1.012)	0.914
PM <sub>10</sub> (µg/m³)	1.008 (1.001 - 1.014)	0.027	1.009 (1.002 - 1.016)	0.012

474 Adjusted for Age, body mass index, diabetes mellitus, dyslipidemia, heart failure,

475 hypertension, previous ischemic heart disease, sex, smoking status, stroke, symptom onset.

476 CI, confidence interval; CO, carbon monoxide; NO<sub>2</sub>, nitric dioxide; O<sub>3</sub>, ozone; OR, odds ratio;

477  $PM_{10}$ , particulate matter 10  $\mu$ m or less in diameters; ppb, part per billion; ppm, part per

478 million; SO<sub>2</sub>, sulfur dioxide.

480 Table 4. Univariate and multivariate regression analysis between the incidence of

481 cardiogenic shock events and the annual average concentration of each air pollutant before 482

483

the symptom date of myocardial infarction.

	Univariate		Multivariate	
	OR (95% CI)	P value	OR (95% CI)	P value
SO <sub>2</sub> (ppb)	1.122 (1.021 - 1.234)	0.017	1.104 (1.006 - 1.212)	0.037
CO (ppm)	1.090 (0.960 - 1.238)	0.182	1.076 (0.949 - 1.219)	0.254
O <sub>3</sub> (ppb)	0.889 (0.853 - 0.926)	< 0.001	0.891 (0.857 - 0.928)	< 0.001
NO <sub>2</sub> (ppb)	1.013 (0.985 - 1.041)	0.365	1.015 (0.988 - 1.042)	0.269
$PM_{10}  (\mu g/m^{s})$	1.036 (1.019 - 1.053)	< 0.001	1.033 (1.018 - 1.050)	< 0.001

484 Adjusted for age, body mass index, diabetes mellitus, dyslipidemia, heart failure,

485 hypertension, left ventricular ejection fraction, percutaneous coronary intervention, previous

486 ischemic heart disease, sex, smoking status, STEMI status, stroke, and symptom date. CI,

487 confidence interval; CO, carbon monoxide; NO<sub>2</sub>, nitric dioxide; O<sub>3</sub>, ozone; OR, odds ratio;

488 PM<sub>10</sub>, particulate matter 10 µm or less in diameter; ppb, part per billion; ppm, part per million;

489 SO<sub>2</sub>, sulfur dioxide.

### 491 Figures and Figure Legends

492



493 494

495 Figure 1. Study flow chart of patient enrollment. AMI, acute myocardial infarction; KAMIR,

496 Korea Acute Myocardial Infarction Registry; MI, myocardial infarction



Figure 2. Spearman correlation coefficients for annual average concentrations of air pollutants. CO, carbon monoxide; NO<sub>2</sub>, nitric dioxide;  $PM_{10}$ , particulate matter 10  $\mu$ m or less in diameter.

### 502 Supplemental data

Figure S1. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the
incidence of STEMI compared with NSTEMI according to an increase of 1 part per billion
SO<sub>2</sub> before the onset of symptoms.

Variables	Numbers	Odds Ratio (95% CI)		P value	P int
Age		1			0.114
$\geq$ 65 years	22479	+	1.042 [0.992 - 1.096]	0.102	
< 65 years	23140		1.028 [0.982 - 1.076]	0.242	
Sex					0.620
Male	32921	+	1.039 [0.992 - 1.089]	0.102	
Female	12698		1.038 [0.983 - 1.096]	0.180	
Hypertension					0.820
Yes	22776	<u> </u>	1.043 [0.997 - 1.092]	0.070	
No	22843		1.026 [0.974 - 1.081]	0.336	
Diabetes		1			0.236
Yes	12596	+	1.048 [0.991 - 1.107]	0.099	
No	33023	÷	1.035 [0.990 - 1.082]	0.133	
Dyslipidemia					0.264
Yes	5082		1.010 [0.944 - 1.081]	0.775	
No	40537	÷	1.036 [0.989 - 1.086]	0.138	
CVA					0.136
Yes	3030		0.984 [0.924 - 1.048]	0.615	
No	42589	÷	1.037 [0.990 - 1.085]	0.122	
Heart failure					0.929
Yes	842		0.986 [0.874 - 1.112]	0.818	
No	44777		1.042 [0.996 - 1.090]	0.075	
Prior IHD		1			0.564
Yes	7027		1.004 [0.951 - 1.059]	0.894	
No	38592		1.041 [0.993 - 1.091]	0.092	
Smoking		1			0.965
Yes	18853		1.017 [0.967 - 1.070]	0.504	
No	26766	+	1.042 [0.991 - 1.095]	0.107	
Family history of C	AD				0.077
Yes	3285	· · · · · •	1.090 [1.014 - 1.173]	0.020	
No	42334	<u>+</u>	1.039 [0.993 - 1.088]	0.099	
		0.9 0.95 1 1.05 1.1 1.1	5 1.2		

506

Figure S2. Subgroup analysis for adjusted odds ratio and 95% confidence interval of the
incidence of STEMI compared with NSTEMI according to an increase of 0.1 part per million

510 CO

Variables	Numbers	Odds Ratio (95% CI)		P value	P int
Age		1			0.459
$\geq$ 65 years	22479		1.056 [0.993 - 1.123]	0.084	
< 65 years	23140		1.008 [0.949 - 1.071]	0.793	
Sex		1			0.895
Male	32921		1.032 [0.972 - 1.094]	0.303	
Female	12698		1.034 [0.972 - 1.100]	0.290	
Hypertension					0.100
Yes	22776		1.033 [0.970 - 1.101]	0.308	
No	22843		1.031 [0.973 - 1.093]	0.304	
Diabetes					0.369
Yes	12596		1.013 [0.945 - 1.085]	0.717	
No	33023		1.042 [0.986 - 1.102]	0.145	
Dyslipidemia					0.492
Yes	5082		1.005 [0.930 - 1.086]	0.903	
No	40537		1.038 [0.979 - 1.101]	0.213	
CVA					0.122
Yes	3030		0.988 [0.919 - 1.062]	0.749	
No	42589		1.036 [0.975 - 1.100]	0.250	
Heart failure					0.104
Yes	842		0.950 [0.860 - 1.050]	0.318	
No	44777		1.037 [0.977 - 1.100]	0.235	
Prior IHD		1			0.142
Yes	7027		1.022 [0.958 - 1.089]	0.514	
No	38592		1.034 [0.974 - 1.098]	0.271	
Smoking					0.549
Yes	18853		1.024 [0.963 - 1.089]	0.450	
No	26766		1.032 [0.971 - 1.097]	0.317	
Family history of C	AD				0.497
Yes	3285		1.026 [0.961 - 1.095]	0.443	
No	42334		1.030 [0.969 - 1.095]	0.349	

511

Figure S3. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the
incidence of STEMI compared with NSTEMI according to an increase of 1 part per billion
O<sub>3</sub> before the onset of symptoms.

Variables	Numbers		Odds Ratio (95% CI)		P value	
Age			1			
≥ 65 years	22479			0.991 [0.972 - 1.010]	0.341	
< 65 years	23140			0.990 [0.971 - 1.009]	0.313	
Sex						
Male	32921			0.986 [0.969 - 1.004]	0.134	
Female	12698			0.997 [0.976 - 1.019]	0.813	
Hypertension						
Yes	22776			0.997 [0.976 - 1.017]	0.749	
No	22843			0.986 [0.967 - 1.005]	0.135	
Diabetes						
Yes	12596			1.001 [0.981 - 1.021]	0.911	
No	33023	-		0.986 [0.968 - 1.004]	0.118	
Dyslipidemia						
Yes	5082	_		0.987 [0.965 - 1.009]	0.241	
No	40537			0.990 [0.971 - 1.009]	0.310	
CVA						
Yes	3030			1.012 [0.981 - 1.044]	0.459	
No	42589	-		0.988 [0.970 - 1.006]	0.179	
Heart failure						
Yes	842			1.005 [0.965 - 1.046]	0.817	
No	44777			0.989 [0.971 - 1.007]	0.211	
Prior IHD			1			
Yes	7027			0.994 [0.972 - 1.017]	0.610	
No	38592	-		0.988 [0.970 - 1.006]	0.196	
Smoking						
Yes	18853			0.991 [0.972 - 1.011]	0.379	
No	26766			0.991 [0.973 - 1.010]	0.359	
amily history of C	AD					
Yes	3285	_		0.988 [0.966 - 1.011]	0.299	
No	42334			0.990 [0.971 - 1.008]	0.270	

516

Figure S4. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the
incidence of STEMI compared with NSTEMI according to an increase of 1 part per billion
NO<sub>2</sub> before the onset of symptoms.

Variables	Numbers	Odds Ratio (95% CI)	P value	P int
Age				0.006
$\geq$ 65 years	22479	0.994 [0.983 - 1.005]	0.274	
< 65 years	23140	1.001 [0.991 - 1.011]	0.910	
Sex				0.014
Male	32921	1.000 [0.988 - 1.011]	0.936	
Female	12698	0.992 [0.981 - 1.003]	0.159	
Hypertension				0.252
Yes	22776	0.994 [0.984 - 1.005]	0.286	
No	22843	1.008 [1.000 - 1.016]	0.051	
Diabetes				0.688
Yes	12596	0.994 [0.984 - 1.004]	0.254	
No	33023	1.000 [0.989 - 1.011]	0.995	
Dyslipidemia				0.458
Yes	5082	0.994 [0.980 - 1.008]	0.399	
No	40537	0.999 [0.987 - 1.011]	0.820	
CVA				0.028
Yes	3030	0.984 [0.974 - 0.994]	0.002	
No	42589	1.000 [0.988 - 1.012]	0.993	
Heart failure				0.167
Yes	842	0.987 [0.965 - 1.010]	0.275	
No	44777	0.999 [0.987 - 1.012]	0.919	
Prior IHD				0.504
Yes	7027	0.993 [0.985 - 1.001]	0.089	
No	38592	1.001 [0.989 - 1.013]	0.899	
Smoking				0.613
Yes	18853	0.996 [0.987 - 1.006]	0.432	
No	26766	0.996 [0.985 - 1.008]	0.541	
Family history of C	AD			0.446
Yes	3285	0.999 [0.989 - 1.010]	0.874	
No	42334	0.998 [0.986 - 1.011]	0.796	
		0.96 0.97 0.98 0.99 1 1.01		

521

523 **Figure S5.** Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the 524 incidence of STEMI compared with NSTEMI according to an increase of 1  $\mu$ g/m<sup>3</sup> PM<sub>10</sub> 525 before the the symptom date.

Variables	Numbers	Odds Ratio (95% CI)	P value	P int
Age				0.355
$\geq$ 65 years	22479	1.009 [1.001 - 1.017]	0.024	
< 65 years	23140	1.006 [0.998 - 1.014]	0.155	
Sex				0.490
Male	32921	1.010 [1.003 - 1.017]	0.004	
Female	12698	1.003 [0.993 - 1.012]	0.598	
Hypertension				0.028
Yes	22776	1.003 [0.995 - 1.011]	0.447	
No	22843	1.012 [1.004 - 1.020]	0.002	
Diabetes				0.395
Yes	12596	1.003 [0.993 - 1.013]	0.588	
No	33023	1.010 [1.003 - 1.017]	0.005	
Dyslipidemia				0.432
Yes	5082	0.993 [0.981 - 1.005]	0.271	
No	40537	1.011 [1.004 - 1.018]	0.003	
CVA				0.533
Yes	3030	1.003 [0.990 - 1.016]	0.656	
No	42589	1.009 [1.002 - 1.016]	0.007	
Heart failure				0.067
Yes	842	0.991 [0.970 - 1.011]	0.368	
No	44777	1.009 [1.002 - 1.016]	0.013	
Prior IHD				0.447
Yes	7027	1.002 [0.991 - 1.012]	0.749	
No	38592	1.009 [1.002 - 1.016]	0.017	
Smoking				0.084
Yes	18853	1.009 [1.001 - 1.017]	0.036	
No	26766	1.006 [0.999 - 1.014]	0.108	
Family history of C	AD			0.868
Yes	3285	1.005 [0.993 - 1.018]	0.425	
No	42334	1.009 [1.002 - 1.016]	0.015	
		0.97 0.98 0.99 1 1.01 1.02		

526

528 Figure S6. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the
529 incidence of in-hospital cardiogenic shock according to an increase of 1 part per billion SO<sub>2</sub>

22479 23140 32921 12698 — 22776 22843	1.105 [0.998 - 1.222] 1.093 [1.007 - 1.187] 1.124 [1.035 - 1.221] 1.065 [0.970 - 1.169] 1.084 [0.993 - 1.184]	0.054 0.034 0.006 0.186	0.670
22479 23140 32921 12698 — 22776 22843	1.105 [0.998 - 1.222] 1.093 [1.007 - 1.187] 1.124 [1.035 - 1.221] 1.065 [0.970 - 1.169] 1.084 [0.993 - 1.184] 1.093 [1.007 - 1.210]	0.054 0.034 0.006 0.186	0.09
23140 32921 12698 — 22776 22843	1.093 [1.007 - 1.187] 1.124 [1.035 - 1.221] 1.065 [0.970 - 1.169] 1.084 [0.993 - 1.184] 1.021 003 - 1.210]	0.034 0.006 0.186	0.095
32921 12698 - 22776 22843	1.124 [1.035 - 1.221] 1.065 [0.970 - 1.169] 1.084 [0.993 - 1.184]	0.006 0.186	0.095
32921 12698 - 22776 22843	1.124 [1.035 - 1.221] 1.065 [0.970 - 1.169] 1.084 [0.993 - 1.184]	0.006	0.64
12698 - 22776 22843	1.065 [0.970 - 1.169] 1.084 [0.993 - 1.184]	0.186	0.644
22776 22843	1.084 [0.993 - 1.184]		0.60
22776 22843	1.084 [0.993 - 1.184]	0.000	0.000
22843		0.072	
12507	1.103 [1.005 - 1.210]	0.038	
12507			0.942
12390	1.071 [0.967 - 1.186]	0.190	
33023	1.109 [1.014 - 1.213]	0.024	
		1000	0.831
5082	1.009 [0.890 - 1.143]	0.890	
40537	1 124 [1 019 - 1 239]	0.020	
40257	1	0.020	0.135
3030	1151[1013-1308]	0.031	0.150
42589		0.067	
42569		0.007	0.050
842	1 120 00 062 1 5121	0.021	0.050
44777	1.101 [1.003 - 1.208]	0.031	
44777	1.101 [1.003 - 1.208]	0.042	0.025
7027		-0.001	0.055
28502	1.184 [1.077 - 1.302]	< 0.001	
38392	1.077 [0.982 - 1.182]	0.117	0.52
10052		-0.001	0.524
18853	1.176 [1.078 - 1.283]	<0.001	
26766	1.047 [0.953 - 1.150]	0.340	
	!		0.523
3285	1.043 [0.919 - 1.185]	0.512	
42334	1.098 [1.002 - 1.203]	0.046	
	i _		0.337
25093	1.101 [1.001 - 1.212]	0.049	
20526	1.086 [0.967 - 1.219]	0.163	
			0.088
39847 -	1.074 [0.974 - 1.185]	0.153	
5772	1.159 [1.064 - 1.262]	0.001	
			0.967
29402	1.076 [0.983 - 1.178]	0.113	
16217	1.126 [1.030 - 1.232]	0.009	
	38592     -       18853     -       26766     -       3285     -       42334     -       25093     -       20526     -       39847     -       5772     -       29402     -       16217     -	38592       1.077 [0.982 - 1.182]         18853       1.176 [1.078 - 1.283]         26766       1.043 [0.919 - 1.185]         3285       1.043 [0.919 - 1.185]         42334       1.098 [1.002 - 1.203]         25093       1.101 [1.001 - 1.212]         20526       1.086 [0.967 - 1.219]         39847       1.074 [0.974 - 1.185]         5772       1.159 [1.064 - 1.262]         29402       1.076 [0.983 - 1.178]         16217       1.126 [1.030 - 1.232]	38592       1.077 [0.982 - 1.182]       0.117         18853       1.176 [1.078 - 1.283]       <0.001

530 before symptom onset.

531

Figure S7. Subgroup Analysis for adjusted odds ratio and 95% confidence interval of the
incidence of in-hospital cardiogenic shock according to an increase of 0.1 part per million CO

535 before symptom date.

Age $2 \le 65 \text{ years}$ $22479$ $1.08 (0.988 - 1.243)$ $0.61$ Sex $0.21$ $0.81$ $0.81$ $0.81$ Sex $0.21$ $0.284$ $0.21$ $0.284$ Hypertension $0.41$ $0.298 + 1.221$ $0.2284$ $0.466$ No       22843 $0.41$ $0.081$ $0.466$ No       22843 $0.616$ $0.616$ $0.616$ No       22843 $0.4102 + 1.221$ $0.228$ $0.466$ No       22843 $0.616$ $0.616$ $0.616$ No       303023 $0.4102 + 1.253$ $0.446$ $0.616$ No       303023 $1.105 [0.977 + 1.246]$ $0.113$ $0.616$ No       40537 $0.996 + 1.200$ $0.606$ $0.616$ No       42589 $1.003 [0.996 + 1.200]$ $0.660$ $0.107 [0.928 + 1.244]$ $0.147$ Yes       842 $0.997 [0.928 + 1.244]$ $0.141$ $0.97 [0.926 + 1.244]$ $0.147$ Yes       9030 $0.660$ $0.97 [0.926 + 1.244]$ $0.147$ $0.141$ <td< th=""><th>Variables</th><th>Numbers</th><th>Odds Ratio (95% CI)</th><th></th><th>P value</th><th>P int</th></td<>	Variables	Numbers	Odds Ratio (95% CI)		P value	P int
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Age					0.632
< 65 years	$\geq$ 65 years	22479	÷	1.108 [0.988 - 1.243]	0.081	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	< 65 years	23140		1.088 [0.951 - 1.244]	0.221	
	Sex					0.211
Female       12698       1.110 [0.984 - 1.251]       0.089         Hypertension       0.4         No       22843       1.071 [0.929 - 1.235]       0.344         Diabetes       0.6         Yes       1.033 [0.977 - 1.246]       0.113         No       33023       1.003 [0.977 - 1.246]       0.113         Dyslipidemin       0.8       0.93023       0.060         No       40537       1.093 [0.996 - 1.200]       0.060         No       42589       0.044       0.977 [0.968 - 1.244]       0.147         CVA       0.093 [0.996 - 1.200]       0.0001       0.935 - 1.205]       0.355         Heart failure       0.57       0.355       0.111       0.111       0.111         No       42589       1.047 (0.995 - 1.225]       0.197       0.977         Prior IHD       0.038 (0.959 - 1.225]       0.197       0.81         Yes       7027       1.131 [1.005 - 1.271]       0.111         No       38592       1.036 [0.951 - 1.218]       0.247         Smoking       0.24766       1.094 [0.958 - 1.248]       0.184         Yes       28503       1.028 [0.935 - 1.206]       0.790         No       25076       1.03	Male	32921		1.079 [0.954 - 1.221]	0.228	
Hypertension       0.4         Yes       22776       0.44         No       22843       1.071 [0.929 - 1.235]       0.344         Diabetes       0.61       1.071 [0.929 - 1.235]       0.113         No       33023       1.105 [0.975 - 1.253]       0.119         Dyslipidemin       0.8       0.977 [0.968 - 1.244]       0.147         CVA       1.097 [0.968 - 1.244]       0.147       0.147         Yes       3030       1.085 [0.995 - 1.205]       0.355         Heart failue       0.57       0.197       0.111         No       42589       1.084 [0.995 - 1.205]       0.355         Heart failue       0.57       0.197       0.111         No       42589       1.114 [0.976 - 1.271]       0.111         No       42589       1.114 [0.976 - 1.271]       0.111         No       42589       0.197       0.197        Prior HD       0.88       0.88         Yes       7027       0.131 [1.005 - 1.272]       0.041         No       3259       0.355       0.355         Yes       1.8853       1.094 [0.958 - 1.248]       0.184         No       26766       1.126 [1.009 - 1.258]       0.355 <td>Female</td> <td>12698</td> <td></td> <td>1.110 [0.984 - 1.251]</td> <td>0.089</td> <td></td>	Female	12698		1.110 [0.984 - 1.251]	0.089	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Hypertension		i 🔁			0.446
No         22843         1.071 [0.929 - 1.235]         0.344           Dinhetes         0.68           Yes         1.038 [0.977 - 1.246]         0.113           No         33023         1.105 [0.975 - 1.253]         0.119           Dyslipidemin         0.84         0.977 - 1.246]         0.113           Yes         5082         1.093 [0.977 - 1.246]         0.147           CVA         0.997 [0.968 - 1.200]         0.660           No         40537         0.147           CVA         0.147         0.147           Yes         3030         1.188 [1.094 - 1.290]         <0.001           No         42589         1.062 [0.935 - 1.205]         0.147           Yes         842         0.141         0.976 [0.958 - 1.244]         0.147           No         44777         0.111         0.062 [0.935 - 1.205]         0.197           Prior IHD         0.88         0.052         0.997         0.958         0.247           No         26766         1.094 [0.958 - 1.248]         0.184         0.247           Smoking         0.0256         0.035         0.395         0.395           Yes         3285         0.0256         0.194         0.246<	Yes	22776		1.120 [1.002 - 1.253]	0.046	
Diabetes       0.60         Yes       12596         No       33023         Dyslipidemin       0.8         Yes       5082         No       40537         CVA       0.1097 [0.996 - 1.200]       0.660         No       42589       1.093 [0.996 - 1.200]       0.660         Heart failure       0.14       0.147       0.147         Yes       3030       1.188 [1.094 - 1.290]       <0.001	No	22843		1.071 [0.929 - 1.235]	0.344	
Yes       12596 $1.103 [0.977 - 1.246]$ $0.113$ No       33023 $1.105 [0.975 - 1.253]$ $0.119$ Dyslipidemia       0.84         Yes       5082 $1.093 [0.996 - 1.200]$ $0.060$ No       40537 $1.097 [0.968 - 1.244]$ $0.147$ CVA       0.102 [0.935 - 1.205] $0.355$ Heart failure       0.57 $0.935 - 1.205]$ $0.355$ Yes       842 $1.114 [0.976 - 1.271]$ $0.111$ No       44777 $0.957 - 1.225]$ $0.977$ Prior IHD       0.84 $0.57$ $0.957 - 1.225]$ $0.977$ No       38592 $1.114 [0.976 - 1.271]$ $0.111$ $0.57$ Smoking       0.38 $0.976 - 1.272]$ $0.041$ $0.57$ Yes       18853 $1.094 [0.958 - 1.248]$ $0.184$ $0.57$ Smoking $0.976 - 0.271$ $0.37$ $0.37$ $0.37$ Yes       3285 $1.094 [0.958 - 1.248]$ $0.184$ $0.38$ Yes       3285 $0.356$ $0.370 = 0.371$ $0.370 = 0.371$ Yes       32847	Diabetes					0.680
No       33023       1.105 $[0.975 - 1.253]$ 0.119         Dyslipidemia       0.8         Yes       5082       1.093 $[0.996 - 1.200]$ 0.060         No       40537       1.097 $[0.968 - 1.244]$ 0.147         CVA       0.14       0.147       0.147         Yes       3030       1.188 $[1.094 - 1.290]$ <0.001	Yes	12596		1.103 [0.977 - 1.246]	0.113	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	No	33023		1.105 [0.975 - 1.253]	0.119	
Yes       5082       1.093 $[0.996 - 1.200]$ 0.060         No       40537       0.14         CVA       0.14         Yes       3030       0.14         No       42589       1.188 $[1.094 - 1.290]$ 0.001         Heart failure       0.57       0.355         Yes       842       1.114 $[0.976 - 1.271]$ 0.111         No       44777       1.084 $[0.959 - 1.225]$ 0.357         Prior IHD       0.83       0.38       0.38         Yes       7027       1.031 $[1.005 - 1.272]$ 0.041         No       38592       1.076 $[0.951 - 1.218]$ 0.247         Smoking       0.35       0.35       0.35         Yes       1.082 $[0.399 - 1.206]$ 0.790       0.35         No       26766       1.126 $[1.009 - 1.258]$ 0.35         Family history of CAD       0.39       0.39       0.35         Yes       3285       1.028 $[0.931 - 1.218]$ 0.246         No       20526       1.036 $[0.913 - 1.177]$ 0.581         Yes       39847       0.36       0.36       0.39         No       5772       1.036 $[0.913 - 1.177]$ 0.581	Dyslipidemia					0.841
No       40537       1.097 [0.968 - 1.244]       0.147         Yes       3030       0.147       0.147         No       42589       1.188 [1.094 - 1.290]       <0.001	Yes	5082		1.093 [0.996 - 1.200]	0.060	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	No	40537		1.097 [0.968 - 1.244]	0.147	
Yes       3030 No       42589       1.188 [1.094 - 1.290]       <0.001 1.062 [0.935 - 1.205]       0.355         Heart failure       0.57       0.355       0.57         Yes       842 No       1.114 [0.976 - 1.271]       0.111       0.81         Yes       7027 No       38592       0.197       0.81         Smoking       0.57       0.951       0.957         Yes       18853 No       26766       0.951 - 1.218]       0.247         Family history of CAD       0.35       0.035       0.356         Yes       3285 No       25093       0.0790       0.790         STEMI       0.281 [0.391 - 1.218]       0.246       0.043         Yes       25093 No       25093       0.0750       0.39         Yes       39847 No       0.3526       0.035       0.043         PCI       0.036 [0.913 - 1.177]       0.581       0.043         No       50%       29402       1.116 [0.986 - 1.264]       0.083         < 50%	CVA		!	•		0.143
No       42589       1.062 [0.935 - 1.205]       0.355         Heart failure       0.57         Yes       842       1.114 [0.976 - 1.271]       0.111         No       44777       1.084 [0.959 - 1.225]       0.197         Prior IHD       0.88         Yes       785       7027       0.041         No       38592       1.094 [0.958 - 1.248]       0.184         Smoking       0.57       0.57         Yes       18853       0.247       0.57         Smoking       0.58       0.247       0.51         Yes       18853       0.247       0.52         No       26766       1.094 [0.958 - 1.248]       0.184         Prior IHD       0.39       0.59       0.39         Yes       3285       0.041       0.051 - 0.258]       0.035         Smoking       0.028 [0.839 - 1.260]       0.79       0.52         No       20526       0.1087 [0.963 - 1.226]       0.179         STEMI       0.36 [0.913 - 1.177]       0.581       0.06         No       20526       1.036 [0.913 - 1.177]       0.581         No       5772       1.036 [0.913 - 1.177]       0.581         L	Yes	3030		1.188 [1.094 - 1.290]	< 0.001	
Heart failure       0.5'         Yes       842         No       44777         Prior IHD       0.81         Yes       7027         No       38592         Smoking       0.5'         Yes       1.034 [0.959 - 1.225]       0.197         Smoking       0.5'         Yes       1.036 [0.951 - 1.218]       0.247         Smoking       0.35         Yes       1.094 [0.958 - 1.248]       0.184         No       26766       1.094 [0.958 - 1.248]       0.184         No       26766       1.028 [0.839 - 1.260]       0.790         Stemi       0.35       0.35       0.35         Yes       3285       1.028 [0.839 - 1.260]       0.790         No       42334       0.144       0.043         Yes       25093       1.076 [0.951 - 1.218]       0.246         No       5772       1.036 [0.913 - 1.177]       0.581         LVEF       0.02       1.036 [0.913 - 1.177]       0.581         No       5772       1.116 [0.986 - 1.264]       0.083         <50%	No	42589		1.062 [0.935 - 1.205]	0.355	
Yes       842       1.114 [0.976 - 1.271]       0.111         No       44777       1.084 [0.959 - 1.225]       0.197         Prior IHD       0.88       0.131 [1.005 - 1.272]       0.041         Yes       7027       1.131 [1.005 - 1.272]       0.041         No       38592       1.076 [0.951 - 1.218]       0.247         Smoking       0.52       0.035       0.53         Yes       3285       1.094 [0.958 - 1.248]       0.184         No       26766       1.126 [1.009 - 1.258]       0.035         Family history of CAD       0.33       0.39       1.028 [0.839 - 1.260]       0.790         No       42334       1.026 [0.951 - 1.218]       0.246       0.035         STEMI       0.38       0.043       0.043       0.043         Yes       25093       1.036 [0.913 - 1.177]       0.581         No       25772       1.345 [1.160 - 1.558]       <0.001	Heart failure					0.573
No       44777 $1.084 [0.959 - 1.225]$ $0.197$ Prior IHD $0.81$ Yes $7027$ $0.041$ No $38592$ $1.076 [0.951 - 1.218]$ $0.247$ Smoking $0.52$ $0.97$ $0.52$ Yes $18853$ $0.941$ $0.790$ No $26766$ $1.094 [0.958 - 1.248]$ $0.184$ Family history of CAD $0.39$ $0.39$ $0.35$ Yes $3285$ $1.028 [0.839 - 1.260]$ $0.790$ No $42334$ $1.076 [0.951 - 1.218]$ $0.246$ No $20526$ $1.076 [0.951 - 1.218]$ $0.246$ No $20526$ $1.036 [0.913 - 1.177]$ $0.581$ No $5772$ $1.036 [0.913 - 1.177]$ $0.581$ No $5772$ $1.036 [0.913 - 1.177]$ $0.581$ LVEF $0.996 - 1.264]$ $0.083$ $0.77$ $\geq 50\%$ $29402$ $1.116 [0.986 - 1.264]$ $0.083$ $< 50\%$ $16217$ $1.016 [0.973 - 1.257]$ $0.123$	Yes	842	1	1.114 [0.976 - 1.271]	0.111	
Prior IHD       0.81         Yes       7027         No       38592         Smoking       0.247         Yes       1.034 [0.055 - 1.218]       0.247         Smoking       0.52         Yes       3285       0.035         Family history of CAD       0.33         Yes       3285         No       42334         Yes       25093         Yes       39847         No       5772         LVEF       0.035         ≥ 50%       29402         < 50%	No	44777		1.084 [0.959 - 1.225]	0.197	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Prior IHD		_			0.880
No $38592$ $1.076$ [ $0.951 - 1.218$ ] $0.247$ Smoking $0.55$ $0.951 - 1.218$ ] $0.247$ No $26766$ $1.094$ [ $0.958 - 1.248$ ] $0.184$ Family history of CAD $0.35$ Yes $3285$ $1.028$ [ $0.839 - 1.260$ ] $0.790$ No $42334$ $1.087$ [ $0.963 - 1.260$ ] $0.790$ STEMI $0.2526$ $0.1145$ [ $1.004 - 1.306$ ] $0.043$ PCI $0.35266$ $1.036$ [ $0.913 - 1.177$ ] $0.581$ No $5772$ $1.036$ [ $0.913 - 1.177$ ] $0.581$ LVEF $0.39$ $0.001$ $0.77$ $\geq 50\%$ $29402$ $1.116$ [ $0.986 - 1.264$ ] $0.083$ $1.016$ [ $0.973 - 1.257$ ] $0.123$	Yes	7027		1.131 [1.005 - 1.272]	0.041	
Smoking       0.52         Yes       18853         No       26766         Family history of CAD       0.35         Yes       3285         No       42334         Yes       25093         No       20526         PCI       0.36         Yes       39847         No       5772         LVEF       0.036 $\geq 50\%$ 29402 $< 50\%$ 16217	No	38592		1.076 [0.951 - 1.218]	0.247	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Smoking		_			0.524
No       26766       1.126 [1.009 - 1.258]       0.035         Family history of CAD       0.39         Yes       3285       1.028 [0.839 - 1.260]       0.790         No       42334       1.087 [0.963 - 1.226]       0.179         STEMI       0.88       0.036       0.043         Yes       25093       1.076 [0.951 - 1.218]       0.246         No       20526       1.145 [1.004 - 1.306]       0.043         PCI       0.036 [0.913 - 1.177]       0.581         No       5772       1.345 [1.160 - 1.558]       <0.001	Yes	18853		1.094 [0.958 - 1.248]	0.184	
Family history of CAD       0.33         Yes       3285         No       42334         Yes       25093         No       20526         PCI       0.36         Yes       39847         No       5772         LVEF $\geq$ 50% $\geq$ 50%       29402 $<$ 50%       16217	No	26766		1.126 [1.009 - 1.258]	0.035	
Yes       3285 $1.028 [0.839 - 1.260]$ $0.790$ No       42334 $1.087 [0.963 - 1.226]$ $0.179$ STEMI       0.88         Yes       25093 $1.076 [0.951 - 1.218]$ $0.246$ No       20526 $1.145 [1.004 - 1.306]$ $0.043$ PCI       0.036 [0.913 - 1.177] $0.581$ No       5772 $1.345 [1.160 - 1.558]$ $<0.001$ LVEF       0.083 $<0.083$ $0.072$ $\leq 50\%$ 16217 $0.123$ $0.123$	Family history of C	AD	_			0.395
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Yes	3285		1.028 [0.839 - 1.260]	0.790	
STEMI       100 100 100 100 100 100 100 100 100 100	No	42334		1.087 [0.963 - 1.226]	0.179	
Yes       25093 No $1.076 [0.951 - 1.218]$ $0.246$ PCI       0.001       0.003         Yes       39847 No $5772$ $1.036 [0.913 - 1.177]$ $0.581$ LVEF $250\%$ $29402$ $1.116 [0.986 - 1.264]$ $0.083$ $< 50\%$ $16217$ $0.123$ $0.123$	STEMI		_	1.007 [0.705 1.220]	0.177	0.881
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Yes	25093		1.076 [0.951 - 1.218]	0.246	0.001
PCI       0.03         Yes       39847       1.036 $[0.913 - 1.177]$ 0.581         No       5772       1.345 $[1.160 - 1.558]$ <0.001         LVEF       0.77 $\geq 50\%$ 29402       1.116 $[0.986 - 1.264]$ 0.083         < 50%       16217       0.123	No	20526		1 145 [1 004 - 1 306]	0.043	
Yes       39847 $1.036 [0.913 - 1.177]$ $0.581$ No       5772 $1.345 [1.160 - 1.558]$ $<0.001$ LVEF $250\%$ $29402$ $1.116 [0.986 - 1.264]$ $0.083$ $< 50\%$ $16217$ $1.016 [0.973 - 1.257]$ $0.123$	PCI	20520	-	1145 [1.004 - 1.500]	0.045	0.052
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Vee	39847		1 036 [0 913 - 1 177]	0.581	0.002
LVEF $0.77$ $\geq 50\%$ 29402 $< 50\%$ 16217	No	5772	-	1 345 [1 160 - 1 558]	<0.001	
$ \geq 50\% \qquad 29402 \qquad \qquad 1.116 \ [0.986 - 1.264] \qquad 0.083 \\ < 50\% \qquad 16217 \qquad \qquad 1.106 \ [0.973 - 1.257] \qquad 0.123 $	LVEF	5772	-	1.545 [1.100 - 1.550]	-0.001	0 774
< 50% 16217 1.106 [0.973 - 1.257] 0.123	> 50%	29402	<u>i</u>	1 116 [0 986 - 1 264]	0.083	0.774
	< 50%	16217		1.110 [0.980 - 1.204]	0.123	
	< 50%	10217		1.100 [0.975 - 1.257]	0.125	

536

Figure S8. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the
incidence of in-hospital cardiogenic shock according to an increase of 1 part per billion O<sub>3</sub>.

Age         ≥ 65 years       22479         < 65 years       23140         Sex       32921         Female       12698         Hypertension       22776         No       22843         Diabetes       2         Yes       12596         No       33023         Dyslipidemia       2         Yes       5082         No       40537         CVA       2         Yes       3030         No       42589         Heart failure       Yes         Yes       842         No       44777         Prior IHD       Yes       7027		0.888 [0.850 - 0.928] 0.916 [0.882 - 0.951]	<0.001 <0.001	0.027
≥ 65 years 22479  < 65 years 23140  Sex  Male 32921  Female 12698  Hypertension  Yes 22776  No 22843  Diabetes  Yes 12596  No 33023  Dyslipidemia  Yes 5082  No 40537  CVA  Yes 3030  No 42589  Heart failure  Yes 842  No 44777  Prior IHD  Yes 7027		0.888 [0.850 - 0.928] 0.916 [0.882 - 0.951]	<0.001 <0.001	
<65 years 23140 Sex Male 32921 Female 12698 Hypertension Yes 22776 No 22843 Diabetes Yes 12596 No 33023 Dyslipidemia Yes 5082 No 40537 CVA Yes 3030 No 42589 Heart failure Yes 842 No 44777 Prior IHD Yes 7027		0.916 [0.882 - 0.951]	< 0.001	
Male         32921           Female         12698           Hypertension         -           Yes         22776           No         22843           Diabetes         -           Yes         12596           No         33023           Dyslipidemia         -           Yes         5082           No         40537           CVA         -           Yes         3030           No         42589           Heart failure         -           Yes         842           No         44777           Prior IHD         -           Yes         7027				
Male         32921           Female         12698           Hypertension         -           Yes         22776           No         22843           Diabetes         -           Yes         12596           No         33023           Dyslipidemia         -           Yes         5082           No         440537           CVA         -           Yes         3030           No         42589           Heart failure         -           Yes         842           No         44777           Prior IHD         -           Yes         7027				0.801
Female         12698           Hypertension         Yes         22776           No         22843         22843           Diabetes         Yes         12596           Yes         12596         30023           Dyslipidemia         Yes         5082           Yes         5082         3030           Ov         42589         Heart failure           Yes         842         No         44777           Prior IHD         Yes         7027		0.893 [0.858 - 0.929]	< 0.001	
Hypertension           Yes         22776           No         22843           Dinbetes         2           Yes         12596           No         33023           Dyslipidemia         2           Yes         5082           No         40537           CVA         2           Yes         3030           No         42589           Heart failure         2           Yes         842           No         44777           Prior IHD         2           Yes         7027	i	0.909 [0.870 - 0.951]	< 0.001	
Yes         22776           No         22843           Diabetes         2           Yes         12596           No         33023           Dyslipidemia         2           Yes         5082           No         40537           CVA         3030           Yes         3030           No         42589           Heart failure         2           Yes         842           No         44777           Prior IHD         Yes	- <u>-</u> i			0.509
No         22843           Diabetes         2596           No         33023           Dyslipidemia         2           Yes         5082           No         40537           CVA         3030           Yes         3030           No         40537           CVA         40537           Heart failure         2           Yes         3030           No         442589           Heart failure         2           No         44777           Prior IHD         2           Yes         7027		0.906 [0.873 - 0.941]	< 0.001	
Yes         12596           No         33023           Dyslipidemia		0.890 [0.849 - 0.933]	< 0.001	
Yes         12596           No         33023           Dyslipidemia				0.100
No         33023           Dyslipidemin         -           Yes         5082           No         40537           CVA         -           Yes         3030           No         42589           Heart failure         -           Yes         842           No         44777           Prior IHD         -           Yes         7027		0.890 [0.853 - 0.929]	< 0.001	
Dyslipidemin           Yes         5082           No         40537           CVA		0.903 [0.867 - 0.941]	< 0.001	
Yes         5082           No         40537           CVA				0.276
No         40537           CVA		0.929 [0.884 - 0.976]	0.003	
CVA Yes 3030 No 42589 Heart failure Yes 842 No 44777 Prior IHD Yes 7027		0.891 [0.856 - 0.927]	< 0.001	
Yes         3030           No         42589           Heart failure				0.608
No         42589           Heart failure		0.934 [0.890 - 0.980]	0.006	
Heart failure         Kes         842           No         44777           Prior IHD         Yes         7027	i	0.892 [0.856 - 0.928]	< 0.001	
Yes 842 No 44777 Prior IHD Yes 7027	1			0.624
No 44777 Prior IHD Yes 7027		0.935 [0.882 - 0.991]	0.023	
Prior IHD Yes 7027		0.891 [0.857 - 0.927]	< 0.001	
Yes 7027	1			0.145
		0.906 [0.868 - 0.946]	< 0.001	
No 38592		0.895 [0.859 - 0.934]	< 0.001	
Smoking				0.166
Yes 18853	I	0.909 [0.873 - 0.946]	< 0.001	
No 26766		0.890 [0.854 - 0.929]	< 0.001	
Family history of CAD	1			0.325
Yes 3285		0.965 [0.913 - 1.020]	0.208	
No 42334		0.891 [0.857 - 0.927]	< 0.001	
STEMI		. ,		0.868
Yes 25093		0.897 [0.864 - 0.932]	< 0.001	
No 20526		0.899 [0.856 - 0.945]	< 0.001	
PCI				< 0.00
Yes 39847		0.901 [0.865 - 0.938]	< 0.001	
No 5772		0.865 [0.816 - 0.917]	< 0.001	
LVEF	I			0.986
≥ 50% 29402		0.911 [0.876 - 0.946]	< 0.001	
< 50% 16217		0.883 [0.843 - 0.925]	< 0.001	
		The family and a		

540

542 Figure S9. Subgroup analysis for the adjusted odds ratio and 95% confidence interval of the
543 incidence of in-hospital cardiogenic shock according to an increase of 1 part per billion NO<sub>2</sub>.

Variables	Numbers	Odds Ratio (95% CI)		P value	P int
Age					0.930
≥ 65 years	22479		1.015 [0.990 - 1.041]	0.238	
< 65 years	23140		1.021 [0.999 - 1.044]	0.056	
Sex					0.239
Male	32921		1.019 [0.996 - 1.043]	0.106	
Female	12698		1.015 [0.991 - 1.039]	0.223	
Hypertension					0.934
Yes	22776		1.014 [0.990 - 1.039]	0.253	
No	22843		1.020 [0.994 - 1.046]	0.127	
Diabetes					0.887
Yes	12596		1.015 [0.991 - 1.039]	0.227	
No	33023		1.022 [0.997 - 1.048]	0.081	
Dyslipidemia					0.582
Yes	5082		1.011 [0.992 - 1.031]	0.252	
No	40537		1.014 [0.988 - 1.042]	0.297	
CVA					0.946
Yes	3030		1.013 [0.994 - 1.031]	0.186	
No	42589		1.018 [0.991 - 1.045]	0.193	
Heart failure		1			0.816
Yes	842		1.024 [0.997 - 1.05200	e+000081	
No	44777		1.016 [0.990 - 1.043]	0.229	
Prior IHD		1			0.094
Yes	7027		1.026 [1.006 - 1.046]	0.011	
No	38592		1.014 [0.988 - 1.041]	0.293	
Smoking					0.897
Yes	18853	÷	1.021 [0.998 - 1.045]	0.079	
No	26766		1.013 [0.986 - 1.041]	0.341	
Family history of C	AD				0.734
Yes	3285		1.007 [0.985 - 1.030]	0.549	
No	42334		1.017 [0.991 - 1.044]	0.197	
STEMI			. ,		0.354
Yes	25093		1.015 [0.991 - 1.039]	0.231	
No	20526	i	1.026 [1.004 - 1.049]	0.021	
PCI					0.010
Yes	39847		1.014 [0.989 - 1.039]	0.278	
No	5772		1.038 [1.011 - 1.065]	0.005	
LVEF					0.472
$\geq 50\%$	29402		1.016 [0.992 - 1.041]	0.185	
< 50%	16217		1.024 [1.001 - 1.048]	0.044	
		1 1.02 1.04 1.0	06		

544

546 **Figure S10.** Subgroup analysis for the adjusted odds ratio and 95% confidence interval of 547 the incidence of in-hospital cardiogenic shock according to the increase  $1 \ \mu g/m^3 PM_{10}$  before

548 t	he	symptom	date.
-------	----	---------	-------

Variables	Numbers	Odds Ratio (95% CI)		P value	P int
Age					0.524
≥ 65 years	22479		1.037 [1.019 - 1.055]	< 0.001	
< 65 years	23140		1.031 [1.016 - 1.045]	< 0.001	
Sex		1			0.761
Male	32921		1.031 [1.016 - 1.046]	< 0.001	
Female	12698		1.041 [1.021 - 1.060]	< 0.001	
Hypertension		i			0.715
Yes	22776		1.040 [1.025 - 1.055]	< 0.001	
No	22843		1.026 [1.007 - 1.045]	0.007	
Diabetes					0.721
Yes	12596		1.039 [1.021 - 1.057]	< 0.001	
No	33023		1.032 [1.016 - 1.048]	< 0.001	
Dyslipidemia					0.329
Yes	5082		1.028 [1.011 - 1.045]	0.001	
No	40537		1.033 [1.016 - 1.049]	< 0.001	
CVA					0.802
Yes	3030		1.031 [1.010 - 1.052]	0.003	
No	42589		1.034 [1.017 - 1.051]	< 0.001	
Heart failure					0.922
Yes	842		1.038 [1.013 - 1.063]	0.002	
No	44777		1.033 [1.017 - 1.050]	< 0.001	
Prior IHD		I			0.025
Yes	7027		1.048 [1.031 - 1.066]	< 0.001	
No	38592		1.030 [1.013 - 1.046]	< 0.001	
Smoking		i			0.079
Yes	18853		1.023 [1.008 - 1.039]	0.003	
No	26766		1.043 [1.025 - 1.061]	< 0.001	
Family history of C	AD	i			0.322
Yes	3285		1.008 [0.983 - 1.034]	0.515	
No	42334		1.036 [1.019 - 1.052]	< 0.001	
STEMI					0.386
Yes	25093		1.032 [1.015 - 1.049]	< 0.001	
No	20526		1.041 [1.023 - 1.059]	< 0.001	
PCI					0.046
Yes	39847		1.032 [1.016 - 1.048]	< 0.001	
No	5772	i	1.049 [1.026 - 1.073]	< 0.001	
LVEF					0.282
$\geq 50\%$	29402		1.033 [1.017 - 1.049]	< 0.001	
< 50%	16217		1.034 [1.015 - 1.054]	0.001	
	•	1 1.02 1.04 1.06 1	.08		